Feb 23 (Reuters) - Gilead Sciences said on Monday it will buy cancer therapy partner Arcellx for an implied equity value of ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...

The inaugural direct-to-consumer campaign for the injectable drug debuted earlier this year, centering around a TV ad featuring a remake of Ciara and Missy Elliott’s 2004 hit song “1, 2 Step”—now ...

Gilead Sciences ( GILD) has agreed to acquire biotechnology company Arcellx ( ACLX) for $115 per share in cash at closing and one contingent value right (CVR) of $5 per share, which represents an ...

Gilead Sciences has agreed to buy the rest of development partner Arcellx in a deal that values the biotechnology company at about $7.8 billion at closing.

Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

In 2006, Gilead Sciences and Bristol Myers Squibb left a permanent mark on the HIV treatment paradigm by fusing together three antiretrovirals and creating the ...

Gilead Sciences has agreed to acquire Arcellx for $7.8 billion, the companies said today, in a deal intended to give the buyer full control of the buyout target’s lead candidate, a BCMA-directed ...

In this week's episode of the CNBC Changemakers and Power Players podcast, CNBC Senior Media and Tech Reporter Julia Boorstin spoke with Johanna Mercier, Chief Commercial & Corporate Affairs Officer ...

Gilead Sciences is writing a very large check for a hometown partner, announcing today that it will acquire Redwood City ...

Gilead Sciences Inc. agreed to buy US cancer-focused biotech Arcellx Inc. for as much as $7.8 billion as it seeks to boost its drug pipeline.

At the 2026 Conference on Retroviruses and Opportunistic Infections, Gilead and Merck demonstrated that their respective daily oral HIV drugs can match current therapies in keeping the virus at bay.